Davenport & Co’s Biogen BIIB Stock Holding History

Davenport & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,205	Closed	-$279K	–	1148
2024 Q2	$279K	Sell	1,205 -361	-23%	-$78.5K	﹤0.01%	976
2024 Q1	$338K	Buy	1,566 +280	+22%	+$65.6K	﹤0.01%	913
2023 Q4	$333K	Sell	1,286 -74	-5%	-$18.2K	﹤0.01%	879
2023 Q3	$350K	Buy	1,360 +302	+29%	+$80.8K	﹤0.01%	831
2023 Q2	$301K	Buy	+1,058	New	+$315K	﹤0.01%	885
2020 Q4	–	Sell	-836	Closed	-$237K	–	786
2020 Q3	$237K	Buy	+836	New	+$233K	﹤0.01%	636
2020 Q1	–	Sell	-1,245	Closed	-$369K	–	670
2019 Q4	$369K	Buy	+1,245	New	+$345K	﹤0.01%	541
2015 Q4	–	Sell	-740	Closed	-$216K	–	591
2015 Q3	$216K	Buy	740 +175	+31%	+$57.8K	﹤0.01%	512
2015 Q2	$228K	Sell	565 -15	-3%	-$6.02K	﹤0.01%	516
2015 Q1	$245K	Buy	+580	New	+$229K	﹤0.01%	525
2014 Q4	–	Sell	-965	Closed	-$319K	–	594
2014 Q3	$319K	Sell	965 -450	-32%	-$148K	0.01%	439
2014 Q2	$446K	Sell	1,415 -2	-0.1%	-$602	0.01%	384
2014 Q1	$433K	Buy	+1,417	New	+$450K	0.01%	390

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Davenport & Co's BIIB Position: Q3 2024 in Review

Davenport & Co sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,205 shares — an estimated $279K sold.

Davenport & Co first reported a position in BIIB in Q1 2014 and held it in 13 quarters. The position peaked at $446K in Q2 2014. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Davenport & Co reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Davenport & Co sold 1,205 Biogen shares in Q3 2024, an estimated $279K.
Davenport & Co first reported a position in Biogen in Q1 2014 and held it in 13 quarters.
Davenport & Co's Biogen position peaked at $446K in Q2 2014.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Davenport & Co's 13F filing for Q3 2024, filed 24 Oct 2024.